Zacks Investment Research on MSN
Dexcom's G7 shows strong results in type 2 diabetes CONNECT study
DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...
With Twiist already available in Type 1 diabetes, Sequel has made the automated insulin delivery system available for the Type 2 population.
A wearable blood sugar monitor may help people with type 2 diabetes even when they don't need insulin. In a newly published ...
DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...
Shelomi Sanders, a college hoops player, shares her view on sports, family competition and kid rankings, and talks about her ...
Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, ...
The twiist Automated Insulin Delivery System is now available for adults with insulin-treated type 2 diabetes.
Hello Health Rounds readers! Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a ...
DexCom (DXCM) shares spiked on Thursday after The New England Journal of Medicine published results from the company's CONNECT trial for its G7 insulin pump in type 2 diabetes, supporting potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results